Literature DB >> 35325401

The Underestimated and Overlooked Burden of Diarrhea and Constipation in Cancer Patients.

Alexander R Moschen1, Yossi Sammy2, Zoe Marjenberg3, Amy B Heptinstall3, Nick Pooley3, Agnieszka M Marczewska4.   

Abstract

PURPOSE OF REVIEW: This review aims to summarize and discuss the diverse causes of two major gastrointestinal dysfunction symptoms, diarrhea and constipation, in cancer patients. We also discuss short- and long-term clinical, economic, and humanistic consequences, including the impact on cancer treatment regimens and patient quality of life, highlighting the limitations of the literature. RECENT
FINDINGS: Diarrhea and constipation as a result of cancer and its treatment can risk the success of anti-cancer therapies by requiring treatment delay or withdrawal, and imposes a substantial humanistic burden in patients with cancer. Despite its importance and frequency, gastrointestinal side effects may be overlooked due to the focus on cancer treatment, and the impact on patients may be underestimated. Additionally, the burden reported may not fully reflect current cancer management, particularly the true impact of economic consequences. A full understanding of the burden of diarrhea and constipation in patients with cancer is required, including broad evaluation of clinical considerations, the patient experience, and an updated assessment of economic burden. This would improve caregivers' appreciation of the impact of gastrointestinal dysfunction and aid the prioritization of future research efforts.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Burden of disease; Constipation; Diarrhea; Gastrointestinal dysfunction; Gut microbiome

Mesh:

Year:  2022        PMID: 35325401     DOI: 10.1007/s11912-022-01267-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.945


  31 in total

1.  How does colorectal cancer present? Symptoms, duration, and clues to location.

Authors:  S R Majumdar; R H Fletcher; A T Evans
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

2.  Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

Authors:  Uwe Güth; Mary Elizabeth Myrick; Andreas Schötzau; Nerbil Kilic; Seraina Margaretha Schmid
Journal:  Breast Cancer Res Treat       Date:  2011-07-13       Impact factor: 4.872

3.  Putting social care on the map.

Authors:  Tony G Egan; Chrys Jaye; Jessica Young; Martyn Williamson
Journal:  BMJ       Date:  2017-06-29

4.  Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer.

Authors:  Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss
Journal:  Oncologist       Date:  2018-12-14

5.  Lack of Support and Information Regarding Long-Term Negative Effects in Survivors of Rectal Cancer.

Authors:  Hanna K Sanoff; Wendy Morris; Amber-Lynn Mitcheltree; Samantha Wilson; Jennifer L Lund
Journal:  Clin J Oncol Nurs       Date:  2015-08       Impact factor: 1.027

6.  BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.

Authors:  Bryan P Schneider; Guanglong Jiang; Tarah J Ballinger; Fei Shen; Christopher Chitambar; Rita Nanda; Carla Falkson; Filipa C Lynce; Christopher Gallagher; Claudine Isaacs; Marcelo Blaya; Elisavet Paplomata; Radhika Walling; Karen Daily; Reshma Mahtani; Michael A Thompson; Robert Graham; Maureen E Cooper; Dean C Pavlick; Lee A Albacker; Jeffrey Gregg; Jeffrey P Solzak; Yu-Hsiang Chen; Casey L Bales; Erica Cantor; Bradley A Hancock; Nawal Kassem; Paul Helft; Bert O'Neil; Anna Maria V Storniolo; Sunil Badve; Kathy D Miller; Milan Radovich
Journal:  J Clin Oncol       Date:  2021-12-15       Impact factor: 50.717

7.  Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area.

Authors:  Elizabeth A Holly; Indranushi Chaliha; Paige M Bracci; Manjushree Gautam
Journal:  Clin Gastroenterol Hepatol       Date:  2004-06       Impact factor: 11.382

8.  Symptom-based approach to colorectal cancer: survey of primary care physicians in Italy.

Authors:  F Panzuto; A Chiriatti; S Bevilacqua; P Giovannetti; G Russo; S Impinna; F Pistilli; G Capurso; B Annibale; G Delle Fave
Journal:  Dig Liver Dis       Date:  2003-12       Impact factor: 4.088

9.  Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines.

Authors:  Sebastian Salas-Vega; Othon Iliopoulos; Elias Mossialos
Journal:  JAMA Oncol       Date:  2017-03-01       Impact factor: 31.777

10.  Clinical features of colorectal cancer before diagnosis: a population-based case-control study.

Authors:  W Hamilton; A Round; D Sharp; T J Peters
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

View more
  1 in total

1.  Chemotherapy-associated oral microbiome changes in breast cancer patients.

Authors:  Ingeborg Klymiuk; Ceren Bilgilier; Alexander Mahnert; Andreas Prokesch; Christoph Heininger; Ingeborg Brandl; Hanka Sahbegovic; Christian Singer; Thorsten Fuereder; Christoph Steininger
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.